Detailed Information on Publication Record
2011
The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia
RÁZGA, Filip, Zdeněk RÁČIL, Kateřina MACHOVÁ POLÁKOVÁ, Lucie BUREŠOVÁ, Hana KLAMOVA et. al.Basic information
Original name
The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia
Name in Czech
Prediktivní hodnota exprese genů human organic cation transporter 1 a ABCB1v různých buněčných populacích u pacientů s de novo chronickou myeloidní leukémií
Authors
RÁZGA, Filip (703 Slovakia, guarantor, belonging to the institution), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Kateřina MACHOVÁ POLÁKOVÁ (203 Czech Republic), Lucie BUREŠOVÁ (203 Czech Republic, belonging to the institution), Hana KLAMOVA (203 Czech Republic), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Dana DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution), Václava POLÍVKOVÁ (203 Czech Republic), Petr CETKOVSKÝ (203 Czech Republic) and Jiří MAYER (203 Czech Republic, belonging to the institution)
Edition
International Journal of Hematology, 2011, 0925-5710
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30200 3.2 Clinical medicine
Country of publisher
Japan
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 1.268
RIV identification code
RIV/00216224:14740/11:00053607
Organization unit
Central European Institute of Technology
UT WoS
000297204800017
Keywords in English
human organic cation transporter; ABCB1; chronic myelogenous leukemia
Tags
International impact
Změněno: 12/1/2012 14:44, Mgr. Michal Petr
Abstract
V originále
In this study, we investigated the predictive value of pretreatment mRNA expression levels of hOCT-1 and ABCB1 in different cell populations with regard to the response to therapy at 6 and 12 months of IMA therapy. Expression levels were assessed in peripheral blood (PB) leukocytes (LEU, n = 30), polymorphonuclear cells (PMNC, n = 23), and mononuclear cells (MNC, n = 21) of PB LEU obtained from 30 patients with de novo chronic myelogenous leukemia (CML). Moreover, the available bone marrow cells (BM) were also included and analyzed (BM, n = 11). The PB and BM samples were obtained, processed, and analyzed as previously described. Responses to therapy were classified according the European LeukemiaNet 2009 (ELN) criteria: responders show an optimal response at 6 months and 12 months, while non-responders reflect a suboptimal response or therapy failure. The assessed pretreatment expression levels were stratified into two groups according to the median-a low-mRNA expression group below the median and a high-mRNA expression group equal to or above the median. The statistical evaluation of the data obtained was performed using the Fisher’s exact tests and summarized in Table 2.
Links
MSM0021622430, plan (intention) |
|